Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 476 - 500 of 15869 in total
Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Matched Description: … [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413] …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Approved
Experimental
Matched Iupac: … }-1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indol-3-ium ... sodium 2-{7-[1,1-dimethyl-3-(4-sulfonatobutyl)-1H,2H,3H-benzo[e]indol-2-ylidene]hepta-1,3,5-trien-1-yl …
Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … [A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin ... Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of ... associated with comorbidities such as hypertension, diabetes, and depression. …
Matched Categories: … Hypnotics and Sedatives …
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Matched Iupac: … 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-[(oxan-4-yl)amino]pyrazine …
Matched Description: … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. ... is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and ... This drug was approved after being designed as an orphan drug with a fast track and priority review status …
Matched Salts cas: … 1254053-84-3
Matched Categories: … Antineoplastic and Immunomodulating Agents ... fms-Like Tyrosine Kinase 3, antagonists & inhibitors …
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Description: … This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability ... , severely impacting patient quality of life and survival. ... It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. …
Matched Categories: … Sex Hormones and Insulins …
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Iupac: … 1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea …
Matched Description: … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.
Approved
Investigational
Matched Description: … trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Matched Iupac: … 3-bromo-N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2,6-dimethoxybenzamide …
Matched Categories: … Benzamides and benzamide derivatives …
Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an approximate ratio of 1:1, where both isomers are active ingredients. A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin. A mixture containing only S-forms...
Approved
Experimental
Matched Iupac: … 2-methyl-4-oxo-3-(prop-2-en-1-yl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane …
Matched Description: … A mixture of the two same stereoisomers, but in an approximate ratio of R:S in 1:3, is called esbiothrin ... Bioallethrin refers to a mixture of two of the allethrin isomers (1R,trans;1R and 1R,trans;1S) in an ... synthetic pyrethroid used as a pesticide against household pest insects such as mosquitoes, houseflies and
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full...
Approved
Investigational
Matched Description: … In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. ... Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, ... Chantix, has been associated with seizures and that some patients who drink while taking the drug may …
Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United...
Approved
Matched Description: … It is shown to display synergistic effects with interferon-α and HCV NS5B inhibitor, and additive effects ... The SVR12 was 83% (29/35) in treatment-naïve patients and 86% (19/22) in relapsing patients. ... Like all NS3/4A inhibitors, simeprevir is a serine protease inhibitor in similarity to [DB08873] and
Matched Salts cas: … 1241946-89-3
Matched Categories: … Heterocyclic Compounds, 3-Ring ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in...
Approved
Matched Iupac: … methyl N-[(2S)-1-[(2S)-2-{5-[(9S)-14-{2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin ... 2,7}.0^{11,16}]heptadeca-1(17),2(7),3,5,11(16),12,14-heptaen-5-yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3- …
Matched Description: … for genotype 1 and 97% and 100% for genotype 4 after 12 weeks of treatment. ... achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% ... Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly. …
Matched Categories: … elbasvir and grazoprevir …
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy...
Approved
Matched Description: … Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. ... topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and
Matched Categories: … Alimentary Tract and Metabolism ... phentermine and topiramate …
Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined as an opioid cough suppressant. It belongs to the opioid family of compounds and it is widely used. Pholcodine activity is the suppression of unproductive cough and it also has a mild sedative effect with little...
Approved
Illicit
Matched Description: … Pholcodine formula is 3-o-morpholinoethylmorphine and it is classified as an antitussive which is defined ... It belongs to the opioid family of compounds and it is widely used. ... It is categorized as Class B drug in the UK and officially taken out of the shelves in 2008. …
Matched Categories: … Cough and Cold Preparations ... Opium Alkaloids and Derivatives …
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of...
Approved
Investigational
Matched Iupac: … amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-22-(carbamoylmethyl)-5,47-dichloro-48-{[(2S,3R,4S,5S,6R)-3- …
Matched Description: … [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion ... Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and ... and contains a lower dose of 400 mg. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion...
Approved
Matched Description: … Furthermore, sincalide stimulates the pancreatic secretion of bicarbonate and enzymes. ... It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK- ... Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Iupac: … 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine …
Matched Description: … [L8063] Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized ... [A32023] Adolescent patients with cataplexy also experienced a slight improvement in the frequency and ... treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and
Matched Salts cas: … 903576-44-3
Matched Categories: … Histamine-3 Receptor Antagonist/Inverse Agonist ... Histamine-3 (H3) Receptor Antagonists/Inverse Agonists …
Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG). Rozonolixizumab itself is an IgG4P, an inactive isotype, to reduce the likelihood of unwanted chain exchange. It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia...
Approved
Investigational
Matched Description: … [L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422) ... by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November 2020. ... Rozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Also known as coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and maintaining blood coagulation. Once converted from prothrombin, thrombin converts fibrinogen to fibrin, which, in combination with platelets from the blood, forms a clot. Medical thrombin is a protein substance produced...
Approved
Investigational
Matched Description: … coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and ... Patients who are know or suspected to have antibodies to bovine thrombin and/or bovine factor V should ... These antibodies may subsequently cross-react with endogenous human factor V and lead to its deficiency …
Matched Mixtures name: … BERIPLAST-P COMBI SET 3 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICI …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for...
Approved
Investigational
Matched Description: … Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6 ... ) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity ... granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Matched Description: … It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) ... [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the …
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Approved
Matched Iupac: … 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile …
Matched Description: … Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (> …
Matched Mixtures name: … Alogliptin and Pioglitazone ... Alogliptin and Pioglitazone ... Alogliptin and Pioglitazone …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and alogliptin ... pioglitazone and alogliptin ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits,...
Approved
Investigational
Matched Iupac: … (1R,2S)-2-{[(2,4-dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane …
Matched Description: … receptors, lemborexant and other orexin antagonists (e.g. ... receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and ... potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and
Matched Categories: … Hypnotics and Sedatives ... Sleep Initiation and Maintenance Disorders …
Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Description: … in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and ... L4274,L4278] In the U.S., it is estimated that more than 3,000 people are living with Fabry disease, and ... [L4274] Given the rarity of Fabry disease and the proportion of Fabry disease patients that could …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Displaying drugs 476 - 500 of 15869 in total